We are live on ! Find out more
AVIR icon

Atea Pharmaceuticals
AVIR

69 hedge funds and large institutions have $2.07B invested in Atea Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 69 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

60.41% more ownership

Funds ownership: 0% → 60.41% (+60%)

Holders
69
Holders Change
+69
Holders Change %
–
% of All Funds
1.22%
Holding in Top 10
9
Holding in Top 10 Change
+9
Holding in Top 10 Change %
% of All Funds
0.16%
New
69
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$208M
2
CAM
Cormorant Asset Management
Massachusetts
+$207M
3
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$181M
4
RCM
RA Capital Management
Massachusetts
+$173M
5
PA
Perceptive Advisors
New York
+$100M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
PAMU
26
Pictet Asset Management (UK)
United Kingdom
$6.37M +$4.92M +152,504 New
HA
27
HHLR Advisors
Cayman Islands
$5.22M +$4.03M +125,000 New
Ameriprise
28
Ameriprise
Minnesota
$4.64M +$3.58M +111,176 New
Morgan Stanley
29
Morgan Stanley
New York
$4.45M +$3.44M +106,587 New
Charles Schwab
30
Charles Schwab
California
$3.61M +$2.79M +86,434 New
Alyeska Investment Group
31
Alyeska Investment Group
Illinois
$3.13M +$2.42M +75,000 New
CCM
32
CAAS Capital Management
New York
$2.92M +$2.26M +70,000 New
N
33
Nuveen
North Carolina
$2.22M +$1.71M +53,091 New
LCM
34
Laurion Capital Management
New York
$1.88M +$1.45M +45,000 New
Wellington Management Group
35
Wellington Management Group
Massachusetts
$1.78M +$1.38M +42,715 New
MWNA
36
Marshall Wace North America
New York
$1.75M +$1.35M +42,002 New
JP Morgan Chase
37
JP Morgan Chase
New York
$1.63M +$1.26M +39,126 New
EMG
38
ETF Managers Group
New Jersey
$1.61M +$1.24M +38,543 New
Bank of New York Mellon
39
Bank of New York Mellon
New York
$1.54M +$1.19M +36,819 New
Legal & General Group
40
Legal & General Group
United Kingdom
$1.39M +$1.07M +33,330 New
CAM
41
Congress Asset Management
Massachusetts
$1.38M +$1.06M +33,010 New
Norges Bank
42
Norges Bank
Norway
$1.25M +$967K +30,000 New
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$1.19M +$918K +28,472 New
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$916K +$707K +21,934 New
TD Asset Management
45
TD Asset Management
Ontario, Canada
$864K +$667K +20,687 New
State of Wisconsin Investment Board
46
State of Wisconsin Investment Board
Wisconsin
$840K +$648K +20,100 New
AC
47
Athanor Capital
New York
$706K +$545K +16,896 New
Bank of America
48
Bank of America
North Carolina
$593K +$457K +14,192 New
AllianceBernstein
49
AllianceBernstein
Tennessee
$531K +$409K +12,700 New
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$523K +$403K +12,516 New
1
2
3

AVIR Hedge Fund Activity: Q4 2020 in Review

69 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q4 2020, worth a combined $2.07B.

Buyers outnumbered sellers: 69 funds opened new AVIR positions and 0 closed out — a net gain of 69 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $208M.

  • 69 institutional investors held Atea Pharmaceuticals (AVIR) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $2.07B of Atea Pharmaceuticals stock for Q4 2020.
  • 69 funds opened new Atea Pharmaceuticals positions in Q4 2020 and 0 closed out, a net change of +69 holders.
  • The largest Atea Pharmaceuticals buyer in Q4 2020 was Fidelity Investments, an estimated $208M added.

Based on aggregated 13F filings for Q4 2020.